Metraipolis › archive › dc_28aeca68b392

International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer — Europe PMC PMID:41235190

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41235190
DOI
10.3389/fpubh.2025.1698562
License (as archived)
solo-consultazione
Archived
2026-11-08T23:44:05.346Z
SHA-256 of the archived text
b83a4f1c13bdeb37714cc8c69d9da672bd5a53ce9a218b45e516d06e9e306efe
Stable URL of this page
https://metraipolis.com/documento/dc_28aeca68b392

How to cite

International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer — Europe PMC PMID:41235190 — Europe PMC (en), https://europepmc.org/article/MED/41235190 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_28aeca68b392 (Metraipolis archive dc_28aeca68b392, sha256 b83a4f1c13bdeb37714cc8c69d9da672bd5a53ce9a218b45e516d06e9e306efe)
BibTeX
@misc{dc28aeca68b392,
  title = {International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer — Europe PMC PMID:41235190},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41235190},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_28aeca68b392; sha256 b83a4f1c13bdeb37714cc8c69d9da672bd5a53ce9a218b45e516d06e9e306efe},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41235190. Agents can read the archived copy with the MCP tool read_document.